IQVIA™ Real-World Insights Bibliography

Annualized Hospitalization Rate With Natalizumab vs Fingolimod in Second-Line Treatment for RRMS in the Public Healthcare System in Brazil: A Claim Database Approach
Author(s): Guilherme Silva Julian 1, Ricardo Papaléo Rosim 2, Estela Cristina Carneseca 3, Jéssica Rigolon 2
Affiliations(s): 1 IQVIA Brasil, São Paulo-SP, Brazil. 2 Biogen Brasil, São Paulo-SP, Brazil. 3 Proestat Consultoria Estatística, Ribeirão Preto-SP, Brazil.
Publication(s):  PMID: 32119696 PMCID: PMC7051079 DOI: 10.1371/journal.pone.0229768
Document Type(s): Article,
Countries: Brazil,
Click here for the abstract
C:
Y:
Oncology,
2020
  L:
A:
English
Retrospective database analysis,
  Add to report
 
 
Cost of Macrovascular Complications in People With Diabetes From a Public Healthcare Perspective: A Retrospective Database Study in Brazil
Author(s): Guilherme Silva Julian 1, Daniel Campos 1, Julie Broe Honore 2, Flávia Sauer Tobaruella 3, Jung Hyun Yoon 3, Nino Hallén 2
Affiliations(s): 1 IQVIA Brasil, São Paulo, Brazil. 2 Novo Nordisk A/S, Søborg, Denmark. 3 Novo Nordisk Farmacêutica Do Brasil Ltda, São Paulo, Brazil.
Publication(s):  PMID: 32372710 DOI: 10.1080/13696998.2020.1764966
Document Type(s): Article,
Countries: Brazil,
Click here for the abstract
C:
Y:
Diabetes,
2020
  L:
A:
English
Observational study, Retrospective database analysis,
  Add to report
 
 
Clinical Characteristics of 3,030 Glioblastoma Multiforme (GBM) Patients in High, Upper Middle and Lower Middle Economic Regions Based on Real-World Data (RWD)
Author(s):  Mitrofan L1 , M.R. Krukas-Hampel M.R2 , L.A. Mendoza L.A3
Affiliations(s): IQVIA, Paris, FR; IQVIA New York, US; IQVIA, Prague, CZ
Publication(s):  ESMO 2018
Document Type(s): Poster,
Countries: Australia, Brazil, Canada, France, Germany, Italy, Mexico, Spain, Taiwan, UK,
C:
Y:
Oncology,
2018
  L:
A:
English
  Add to report
 
 
Clinical characteristics of Glioblastoma Multiforme (GBM) Patients Who Reached 400 Days Post Diagnostic from a Retrospective Real-World Data
Author(s):  Mitrofan L.M.1,Krukas-Hampel M.R.2, Mendoza L.A.3
Affiliations(s): 1 IQVIA, Paris, FR; 2IQVIA New York, US; 3IQVIA, Prague, CZ
Publication(s):  ESMO 2018
Document Type(s): Poster,
Countries: Australia, Brazil, Canada, France, Germany, Italy, Mexico, Spain, Taiwan, UK,
C:
Y:
Oncology,
2018
  L:
A:
English
  Add to report
 
 
Direct Costs of Type 2 Diabetes from fhe Brazilian Public Healthcare Sector Perspective
Author(s): Hnoosh A1, Babineaux SM2, Piras de Oliveira C3, McDonell A1, Vega-Hernandez G1
Affiliations(s): 1IMS, London, England, 2Eli Lilly & Company, Indianapolis, IN, USA, 3Eli Lilly do Brasil, Sao Paulo, Brazil
Publication(s):  ISPOR 4th Latin America Conference.
Value in Health 2013
Document Type(s): Poster,
Countries: Brazil,
C:
Y:
Diabetes,
2013
  L:
A:
English
Burden of illness, Cost analysis, Cost of illness,
  Add to report
 
 
Direct Medical Management Costs of Diabetes-Related Complications in Brazil
Author(s): Vega-Hernández G1; Hnoosh A1; Jugrin A1; Todorova L2; Hansen BB3
Affiliations(s): 1 IMS Health, HEOR, London, UK; 2 Novo Nordisk International Operations, Zurich, Switzerland; 3 Novo Nordisk A/S, Soeborg, Denmark
Publication(s):  ISPOR 17th Annual International Meeting, June 2-6 2012, Washington, USA
Document Type(s): Abstract,
Countries: Brazil,
C:
Y:
Diabetes,
2012
  L:
A:
English
Cost analysis,
  Add to report